Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease

Journal of Crohn's and Colitis

Volumn 6, Issue 1, 2012, Pages 77-85

  Blackhouse, Gord ^a   Assasi, Nazila ^a   Xie, Feng ^a,b   Marshall, John ^a,c   Irvine, E Jan ^d,e   Gaebel, Kathryn ^a,b   Campbell, Kaitryn ^a   Hopkins, Rob ^a   O'Reilly, Daria ^a,b   Tarride, Jean Eric ^a,b   Goeree, Ron ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^c HAMILTON HEALTH SCIENCES   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Adalimumab; ; Anti TNF alpha therapy; ; Cost utility; ; Crohn's disease; ; Economic; Infliximab;

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BUDESONIDE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PLACEBO; PREDNISONE;

ARTICLE; CLINICAL TRIAL; COST UTILITY ANALYSIS; CROHN DISEASE; DRUG COST; HEALTH STATUS; HUMAN; PATIENT CARE; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; REMISSION; TREATMENT DURATION; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CANADA; COST-BENEFIT ANALYSIS; CROHN DISEASE; HEALTH CARE COSTS; HUMANS; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84855971512     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2011.07.007     Document Type: Article

References (37)

1. Friedman S., Blumberg R.S. Inflammatory bowel disease. Harrison's online 2008, McGraw-Hill Health Professions Division, New York. 17th ed. D.L. Kasper, E. Braunwald, A.S. Fauci, S.L. Hauser, D.L. Longo, J.L. Jameson, K.J. Isselbacher (Eds.).
2. Tremaine W.J. Refractory IBD: medical management. Neth J Med 1997, 50(2):S12-S14.
3. Bernstein C.N., Wajda A., Svenson L.W., MacKenzie A., Koehoorn M., Jackson M., Fedorak R., Israel D., Blanchard J.F. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am J Gastroenterol 2006, 101(7):1559-1568.
4. Wong J.L.H. Inflammatory bowel disease. Clinic handbook: gastroenterology 2002, Taylor & Francis, Abingdon (UK).
5. Remicade Notices of compliance 2008, Health Canada, Ottawa.
6. Humira Notices of compliance 2008, Health Canada, Ottawa.
7. Sands B.E., Anderson F.H., Bernstein C.N., Chey W.Y., Feagan B.G., Fedorak R.N., Kamm M.A., Korzenik J.R., Lashner B.A., Onken J.E., Rachmilewitz D., Rutgeerts P., Wild G., Wolf D.C., Marsters P.A., Travers S.B., Blank M.A., Van Deventer S.J. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350(9):876-885.
8. Sandborn W.J., Hanauer S.B., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D.G., Panaccione R., Wolf D., Kent J.D., Bittle B., Li J., Pollack P.F. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007, 56(9):1232-1239.
9. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., Rachmilewitz D., Wolf D.C., Olson A., Bao W., Rutgeerts P., ACCENT ISG Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359(9317):1541-1549.
10. Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., MacIntosh D., Panaccione R., Wolf D., Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130(2):323-333.
11. Colombel J.F., Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Panaccione R., Schreiber S., Byczkowski D., Li J., Kent J.D., Pollack P.F. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132(1):52-65.
12. Ndegwa S.L. Adalimumab for refractory Crohn's disease and ulcerative colitis 2007, Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa.
13. Targan S.R., Hanauer S.B., Van Deventer S.J., Mayer L., Present D.H., Braakman T., DeWoody K.L., Schaible T.F., Rutgeerts P.J. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337(15):1029-1035.
14. Assasi N., Blackhouse G., Xie F., Gaebel K., Marshall J., Irvine E.J., Giacomini M., Robertson D., Campbell K., Hopkins R., Goeree R. Anti-TNF-α drugs for refractory inflammatory bowel disease: clinical- and cost-effectiveness analyses [Technology report number 120] 2009, Canadian Agency for Drugs and Technologies in Health, Ottawa.
15. Sandborn W., Lukas M., Rutgeerts P., Pollack P., Kent J. Fully human anti-TNF adalimumab maintains remission for one year in patients with active Crohn's disease: a randomised, controlled cohort [abstract]. Gut 2006, 55(Suppl 2):A27.
16. Sandborn W.J., Rutgeerts P., Enns R., Hanauer S., Colombel J., Panaccione R., Kent J., Pollack P. Adalimumab rapidly induces clinical remission and response in patients with moderate to severe Crohn's disease who had secondary failure to infliximab therapy: results of the GAIN study [abstract]. Am J Gastroenterol 2006, 101(9 Suppl S):S448.
17. Rutgeerts P., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., Rachmilewitz D., Wolf D.C., Olson A., Bao W., Hanauer S.B. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004, 126(2):402-413.
18. Feagan B.G., Panaccione R., Sandborn W.J., D'Haens G.R., Schreiber S., Rutgeerts P.J., Loftus E.V., Lomax K.G., Yu A.P., Wu E.Q., Chao J., Mulani P. Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study. Gastroenterology 2008, 135(5):1493-1499.
19. Silverstein M.D., Loftus E.V., Sandborn W.J., Tremaine W.J., Feagan B.G., Nietert P.J., Harmsen W.S., Zinsmeister A.R. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999, 117(1):49-57.
20. Lemann M. Review article: can post-operative recurrence in Crohn's disease be prevented?. Aliment Pharmacol Ther 2006, 24(Suppl 3):22-28.
21. McLeod R.S., Wolff B.G., Steinhart A.H., Carryer P.W., O'Rourke K., Andrews D.F., Blair J.E., Cangemi J.R., Cohen Z., Cullen J.B. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology 1995, 109(2):404-413.
22. Brignola C., Cottone M., Pera A., Ardizzone S., Scribano M.L., De FR, D'Arienzo A., D'Albasio G., Pennestri D. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology 1995, 108(2):345-349.
23. Caprilli R., Andreoli A., Capurso L., Corrao G., D'Albasio G., Gioieni A., Assuero L.G., Paladini I., Pallone F., Ponti V. Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Aliment Pharmacol Ther 1994, 8(1):35-43.
24. Sutherland L.R., Martin F., Bailey R.J., Fedorak R.N., Poleski M., Dallaire C., Rossman R., Saibil F., Lariviere L. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology 1997, 112(4):1069-1077.
25. Lochs H., Mayer M., Fleig W.E., Mortensen P.B., Bauer P., Genser D., Petritsch W., Raithel M., Hoffmann R., Gross V., Plauth M., Staun M., Nesje L.B. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology 2000, 118(2):264-273.
26. Hanauer S.B., Korelitz B.I., Rutgeerts P., Peppercorn M.A., Thisted R.A., Cohen R.D., Present D.H. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004, 127(3):723-729.
27. Gregor J.C., McDonald J.W.D., Klar N., Wall R., Atkinson K., Lamba B., Feagan B.G. An evaluation of utility measurement in Crohn's disease. Inflamm Bowel Dis 1997, 3(4):265-276.
28. Alberta Health and Wellness Interactive Drug Benefit List 2009, Government of Alberta, Edmonton, Available:, (accessed 2009 Jan 19). https://www.ab.bluecross.ca/dbl/idbl_main1.html.
29. Regie de l'assurance maladie du Quebec List of medications 2008, Gouvernement du Quebec, Quebec.
30. Drug Plan and Extended Benefits Branch Online formulary 2008, Government of Saskatchewan, Regina.
31. Ontario Public Drug Programs Formulary bulletins and notices: notice from executive officer 2009, Ontario Ministry of Health and Long-Term Care, Toronto, [Report No.: April 5, 2007.].
32. Ontario Ministry of Health and Long-Term Care. e-Formulary. Ontario drug benefit formulary/comparative drug index: electronic version. Version 1.4 ed. Toronto: Queen's Printer for Ontario; 2007.
33. Ontario Case Costing Initiative Costing analysis (CAT) tool 2008, Ontario Ministry of Health and Long-Term Care, Toronto.
34. Marshall J.K., Blackhouse G., Goeree R., Brazier N., Irvine E.J., Faulkner L., Dipchand C., O'Brien B.J. Infliximab for the treatment of Crohn's disease: a systematic review and cost utility analysis [Technology report number 24] 2002, Canadian Coordinating Office for Health Technology Assessment, Ottawa.
35. Dretzke J., Round J., Edlin R., Connock M., Hulme C., Czeczot J., Fry-Smith A., McCabe C., Meads C. Use of tumour necrosis factor alpha (TNF α) inhibitors adalimumab and infliximab for Crohn's disease Jul 1 2008, West Midlands Health Technology Assessment Collaboration, University of Birmingham, Birmingham, UK.
36. Yu A.P., Johnson S., Wang S.T., Atanasov P., Tang J., Wu E., Chao J., Mulani P.M. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease. Pharmacoeconomics 2009, 27(7):609-621.
37. Bodger K., Kikuchi T., Hughes D. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther 2009, 30(3):265-274.